AllianceBernstein’s Theravance Biopharma TBPH Stock Holding History

AllianceBernstein’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.31M	Hold	70,080	–	–	﹤0.01%	2224
2025 Q4	$1.31M	Hold	70,080	–	–	﹤0.01%	2222
2025 Q3	$1.02M	Hold	70,080	–	–	﹤0.01%	2346
2025 Q2	$773K	Sell	70,080 -3,300	-4%	-$32.1K	﹤0.01%	2418
2025 Q1	$655K	Sell	73,380 -3,775	-5%	-$35.1K	﹤0.01%	2443
2024 Q4	$726K	Sell	77,155 -1,700	-2%	-$15.5K	﹤0.01%	2483
2024 Q3	$636K	Hold	78,855	–	–	﹤0.01%	2548
2024 Q2	$669K	Buy	78,855 +6,220	+9%	+$56.1K	﹤0.01%	2509
2024 Q1	$652K	Sell	72,635 -5,100	-7%	-$47.3K	﹤0.01%	2466
2023 Q4	$874K	Hold	77,735	–	–	﹤0.01%	2343
2023 Q3	$671K	Hold	77,735	–	–	﹤0.01%	2429
2023 Q2	$805K	Hold	77,735	–	–	﹤0.01%	2391
2023 Q1	$843K	Hold	77,735	–	–	﹤0.01%	2316
2022 Q4	$872K	Hold	77,735	–	–	﹤0.01%	2355
2022 Q3	$788K	Hold	77,735	–	–	﹤0.01%	2417
2022 Q2	$704K	Hold	77,735	–	–	﹤0.01%	2522
2022 Q1	$743K	Buy	77,735 +200	+0.3%	+$1.96K	﹤0.01%	2527
2021 Q4	$857K	Buy	77,535 +6,800	+10%	+$59.3K	﹤0.01%	2528
2021 Q3	$523K	Hold	70,735	–	–	﹤0.01%	2740
2021 Q2	$1.03M	Hold	70,735	–	–	﹤0.01%	2520
2021 Q1	$1.44M	Sell	70,735 -6,000	-8%	-$114K	﹤0.01%	2259
2020 Q4	$1.36M	Hold	76,735	–	–	﹤0.01%	2170
2020 Q3	$1.14M	Sell	76,735 -1,300	-2%	-$24.4K	﹤0.01%	2123
2020 Q2	$1.64M	Buy	78,035 +13,500	+21%	+$347K	﹤0.01%	1953
2020 Q1	$1.49M	Buy	64,535 +300	+0.5%	+$7.51K	﹤0.01%	1847
2019 Q4	$1.66M	Buy	64,235 +1,300	+2%	+$25.3K	﹤0.01%	2059
2019 Q3	$1.23M	Hold	62,935	–	–	﹤0.01%	2171
2019 Q2	$1.03M	Hold	62,935	–	–	﹤0.01%	2301
2019 Q1	$1.43M	Hold	62,935	–	–	﹤0.01%	2083
2018 Q4	$1.61M	Sell	62,935 -700	-1%	-$18.9K	﹤0.01%	1956
2018 Q3	$2.08M	Buy	63,635 +1,800	+3%	+$49.1K	﹤0.01%	1911
2018 Q2	$1.4M	Buy	61,835 +2,200	+4%	+$52.2K	﹤0.01%	2145
2018 Q1	$1.45M	Sell	59,635 -1,600	-3%	-$43.9K	﹤0.01%	2056
2017 Q4	$1.71M	Hold	61,235	–	–	﹤0.01%	1959
2017 Q3	$2.1M	Hold	61,235	–	–	﹤0.01%	1815
2017 Q2	$2.44M	Buy	61,235 +5,100	+9%	+$196K	﹤0.01%	1698
2017 Q1	$2.07M	Sell	56,135 -1,100	-2%	-$35.1K	﹤0.01%	1795
2016 Q4	$1.82M	Hold	57,235	–	–	﹤0.01%	1901
2016 Q3	$2.07M	Sell	57,235 -604	-1%	-$16.8K	﹤0.01%	1741
2016 Q2	$1.31M	Buy	57,839 +25,100	+77%	+$542K	﹤0.01%	2047
2016 Q1	$615K	Buy	32,739 +2,300	+8%	+$37.6K	﹤0.01%	2338
2015 Q4	$499K	Hold	30,439	–	–	﹤0.01%	2454
2015 Q3	$335K	Sell	30,439 -262,338	-90%	-$3.34M	﹤0.01%	2629
2015 Q2	$3.81M	Buy	292,777 +112,080	+62%	+$1.74M	﹤0.01%	1272
2015 Q1	$3.13M	Buy	180,697 +81,527	+82%	+$1.49M	﹤0.01%	1417
2014 Q4	$1.48M	Buy	99,170 +42,559	+75%	+$741K	﹤0.01%	1948
2014 Q3	$1.3M	Sell	56,611 -23	-0%	-$667	﹤0.01%	2024
2014 Q2	$1.8M	Buy	+56,634	New	+$1.7M	﹤0.01%	1850

Other funds holding TBPH

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ICM

Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AllianceBernstein's TBPH Position: Q1 2026 in Review

AllianceBernstein held its Theravance Biopharma (TBPH) position steady in Q1 2026 at 70,080 shares worth $1.31M. The position accounts for ﹤0.01% of the portfolio, ranked #2224.

AllianceBernstein first reported a position in TBPH in Q2 2014 and has held it in 48 quarters since. The position peaked at $3.81M in Q2 2015. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

AllianceBernstein held 70,080 shares of Theravance Biopharma worth $1.31M as of Q1 2026.
AllianceBernstein left its Theravance Biopharma share count unchanged in Q1 2026.
Theravance Biopharma made up ﹤0.01% of AllianceBernstein's portfolio in Q1 2026, its #2224 holding.
AllianceBernstein first reported a position in Theravance Biopharma in Q2 2014 and has held it in 48 quarters since.
AllianceBernstein's Theravance Biopharma position peaked at $3.81M in Q2 2015.
173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.